HI
KNSA icon

Harbour Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Harbour Investments’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144 Hold
3
– – ﹤0.01% 4473
2025
Q4 		$124 Hold
3
– – ﹤0.01% 3723
2025
Q3 		$116 Buy
+3
New +$97 ﹤0.01% 3629

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Harbour Investments's KNSA Position: Q1 2026 in Review

Harbour Investments held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 3 shares worth $144. The position accounts for ﹤0.01% of the portfolio, ranked #4473.

Harbour Investments first reported a position in KNSA in Q3 2025 and has held it in 3 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Harbour Investments held 3 shares of Kiniksa Pharmaceuticals worth $144 as of Q1 2026.
  • Harbour Investments left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4473 holding.
  • Harbour Investments first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.